CYIOS Corporation (PK) (CYIO) Quote

I’m surprised it’s stalled down here for so long. Don’t know what catalyst could get this thing to move anymore 😞

Looking good for a move to .01

Fins out

Think $CYIO will provide additional audited results and/or updates on uplist with annual fins? We need some sort of catalyst, right?

Accumulating 

Agree, I think a nice steady climb upwards... I will be accumulating as it progress... Good Luck to you in the new year

$CYIO overall outlook is positive. OTC markets should pick up with DJT Inauguration and with an up-listing coming.

I see he also mentioned the up listing audit is almost completed as well... with an up list to the OTCQB or higher. This stock is way under valued... over $14 million in revenue and still sub penny... there are a lot of penny stock out there with 1/3 that much revenue

Chairman John O'Shea. "The extraordinary success of our Noir acquisition, which closed on August 10th, has not only strengthened our financial position but also set the foundation for a successful 2025." $CYIO

This news could possibly get some eyes on this, share structure is very low for this kind of revenue... and solid pinksheets are harder and harder to fine these days.

Nice news 

Would be nice if there were more eyes on this... those are some pretty impressive numbers for a stock selling at .0088 should be well over a penny with that kind of revenue

$CYIO NEWS: CYIOS Corp Reports Record $5 Million in Q4 Revenue Through Noir Subsidiary; Noir Full-Year Revenue Exceeds $14.4 Million

01/16/2025 - 08:35 AM
2024 marks a transformative year for CYIOS Corp, with Noir achieving over 200% year-over-year growth; strategic plans set for continued expansion in 2025.

BOCA RATON, FL / ACCESS Newswire / January 16, 2025 / CYIOS Corp (OTC PINK:CYIO) is pleased to announce that its wholly-owned subsidiary, Noir Medical Supplies, delivered a record-breaking $5 million in revenue during Q4 2024. This significant contribution has propelled Noir's full year revenue to over $14.4 million, a substantial increase from $4.55 million in 2023, reflecting over 200% year-over-year growth.

"2024 was a transformative year for CYIOS," stated Chairman John O'Shea. "The extraordinary success of our Noir acquisition, which closed on August 10th, has not only strengthened our financial position but also set the foundation for a successful 2025."

2024 Year in Review

Noir Acquisition: Completed on August 10, 2024, the acquisition has been instrumental in driving revenue growth.

Revenue Milestones:

CYIOS Q3 2024 (August 10 - September 30): $2.93 million in revenue.

CYIOS Q4 2024: Surpassed $5 million in revenue, marking the highest quarterly revenue in the company's history.

Total revenue from Noir post-acquisition (August 10 - December 31): Over $8 million.

Noir's full-year 2024 revenue: Surpassed $14.4 million, significantly exceeding initial expectations of $7-$9 million.

2025 Roadmap and Strategic Focus

CYIOS Corp remains focused on delivering continued revenue growth with a solid foundation firmly in place. Key initiatives for 2025 include:

1. Scaling Noir:

Expanding product offerings and enhancing geographic reach.

Forecasting $15+ million in revenue for Noir in 2025, excluding potential acquisitions.

2. Uplisting Strategy

Completing a two-year PCAOB audit to enhance financial transparency

Aiming for an exchange uplisting to OTCQB or higher

Closing Remarks

"CYIOS Corp is well-positioned to build on its momentum from 2024," said O'Shea, Chairman of CYIOS Corp. "We are confident investors will take notice of our new direction, successful execution driving revenue growth and delivering sustainable value for shareholders in 2025 and beyond. By focusing on revenue growth and margin expansion as the cornerstone of our strategy, we aim to create significant long-term shareholder value. With Noir now having completed two quarters under CYIOS, we anticipate consistent performance that will garner increased attention from the investment community.

We also believe an uplisting to a higher-tier exchange could substantially enhance shareholder value, providing access to a broader investor base. As we continue to execute successfully and address the disparity between Noir revenues-exceeding $14 million 2024, forecasting $15 million + in 2025-and our current market cap valuation, we expect to see a narrowing of this gap, aligning with the valuation of growth companies in our category trading on a multiple of revenues that validate a much higher valuation."

About Noir Medical Supplies

Noir Medical Supplies is a rapidly growing provider of high-quality medical supplies and equipment, offering products from personal protective equipment (PPE) to essential healthcare items for clinics, hospitals, and medical professionals. Founded in 2023, Noir's mission is to solve inventory challenges for healthcare distributors and institutions across the United States and the Caribbean by delivering high-quality products at competitive prices. Noir serves some of the nation's largest healthcare and biotech companies and continues to expand its reach to meet the evolving needs of the healthcare sector.

Additional information regarding clients served as well as distribution partners can be found on the company's website. (https://noirmedicalsupplies.com/)

CYIOS Contact Information

Investors are encouraged to follow CYIOS at: https://twitter.com/cyioscorp

https://www.tiktok.com/@cyioscorp

Public and Investor Relations: admin@cyioscorporation.com

About CYIOS Corporation

CYIOS Corp (OTC PINK: CYIO) is a publicly traded company focused on strategic investments and acquisitions in high-growth sectors, including healthcare, medical technology, and emerging industries. CYIOS Corp is committed to building a portfolio that delivers long-term value to shareholders through innovation and excellence. For more information, please visit: CYIOScorporation.com.

FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements." Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management's current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified using words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "would," "could," "will" & other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company's actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered w/ these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.

SOURCE: CYIOS Corp.
https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/cyios-corp-reports-record-5-million-in-q4-revenue-through-noir-subsidiary-noir-full-year-revenue-exceeds-144-million-969425

Any big news from the Emerging Growth conf yesterday? Catalysts announced?

CYIOS Corporation provides and implements innovative solutions to complex business problems in the areas of consulting, knowledge management, systems integration, application development, program integration, project management, and more. Our solutions integrate industry best practices with Government initiatives to help our customers meet their mission-critical goals.

What does everyone think re recent price action on $CYIO?

LOL! Hi old buddy! Saw a lot of noise about CYIO recently. Not impressed. I don't like all the preferred that can be converted without a registration statement: 4(a)(1) per the filings and I just hate all the convertible notes. Also look at the Q over Q losses. $ 444,890 for the 6 months ended June 30.
At lest old Timmy is out of the picture.
GLTA!

Surf is back = Bullish

Kept seeing about the chat/growth conference. Looks like thy are still feeding J-RICKS LLC Christopher Balmford and a bunch of insiders.
I also see they are ($444,890) in the hole for the first 6 months this year.
Overpriced.

Go CYIOS! Thanks.

Great company!

$CYIO Great catching up with Ralph Amato, CEO of Noir Medical Supplies, our recent acquisition! 🚚📦 Warehouse packed & stacked with medical supply products ready for shipping. Warehouse inventory generally turns every 4-7 days —things are moving fast! #NoirMedical #growth pic.twitter.com/OuDuwUzQiY— CYIOS Corporation (@cyioscorp) September 20, 2024

🚨 $CYIO Updates Coming Soon! Looking forward to present at the next Emerging Growth Conference on Sept. 26 @ 4:25pm ET! Joining Chairman John O’Shea will be Ralph Amato, CEO Noir Medical Supplies, recently acquired by #CYIOS. Expect upwardly revised rev. guidance and a strong…— CYIOS Corporation (@cyioscorp) September 19, 2024

Chart says bottom formed now we turn.

This should be trading in the $0.02-$0.03 range according to value.

OTC is crap.

CYIOS Corporation $CYIO has been on fire lately! The recent product launch exceeded expectations and the market response has been overwhelmingly positive. Definitely a company to watch!

Just read the latest report on CYIOS Corporation $CYIO and the numbers are looking fantastic. Their strategic partnerships are clearly paying off. Great time to be holding this stock!

CYIOS Corporation ($CYIO) is really showing some impressive growth. Their latest innovation is making waves in the industry. Excited to see where this leads in the coming quarters!

Projected growth to $10M revenue in 2025 for Noir Medical Supplies!

$CYIO Live interview link: https://x.com/i/spaces/1lPJqODaLgbKb

Boom

Excited

Expected $10M in revenue for 2025.

Things are really starting to heat up here

Adding a lot here

This acquisition brings a lot of value to CYIO. Over $4.5M in revenue in 2024 and projecting $7M this year. Cash flow positive as well!

Looking forward to the spaces today too: https://x.com/i/spaces/1lPJqODaLgbKb

This lacks volume.

https://noirmedicalsupplies.com/about/

$CYIO Announces it has Closed the Acquisition of Noir Medical Supplies.
Noir Expects to see Strong Revenue Growth in 2024 Exceeding $7 Million, up from $4.6 Million in 2023. https://t.co/kyXiTuahyu

Join us live today at 4:05PM EST for additional information.… pic.twitter.com/UOUC61ox1e— CYIOS Corporation (@cyioscorp) September 11, 2024

$CYIO Announces it has Closed the Acquisition of Noir Medical Supplies.
Noir Expects to see Strong Revenue Growth in 2024 Exceeding $7 Million, up from $4.6 Million in 2023.

https://twitter.com/i/spaces/1lPJqODaLgbKb

Exciting stuff for $CYIO tomorrow. Mr Robot is doing an interview

Medical supply company is juicy.

$CYIO Emerging Growth Conference Highlights

- Executed bonding contract to acquire privately held medical supply company.
- Generated revenue in excess of $4.5 Million last year.
- Experienced management group that has agreed to stay on board.
- 2 well established warehouses in Florida.
- Strong growth pipeline, analyzing additional business models.
- Company accounts being audited.
- Strong revenue forecasts for 2025.
- Acquisition provides long term shareholder value and positive cash flow.

$CYIO spot on analysis in this post!

CYIO Initial valuation and price per share assumptions

Obviously, investors should do their own due diligence and come up with their own valuation model. That being said, I’ve gone ahead and come up with some general targets, based on the currently available public info. I believe we can extrapolate some basic valuation metrics to come up with a projected share price now that this acquisition is officially closed.

Assuming 272 million shares outstanding, here's a breakdown of what the the market cap of the company would be based on reaching various share prices:

• $0.02 per share: Market Cap = $5.4 million (Just over 1x LAST YEAR - 2023 revenues)
• $0.03 per share: Market Cap = $8.1 million
• $0.05 per share: Market Cap = $13.6 million
• $0.06 per share: Market Cap = $16.3 million
• $0.075 per share: Market Cap = $20.4 million
• $0.10 per share: Market Cap = $27 million

What we know so far from the publicly disclosed info is that 2024 & 2025 should have “significant year over year revenue growth”. Let’s just say conservatively it’s approx 50% YOY rev growth. That’s a BIG number!!....which puts us around $6.5-7m in revs for 2024.

Putting a reasonable multiplier of say 2x or 3x on the current year 2024 revs, should give us an idea of where the pps should be perhaps right now, TODAY…not next year, quite literally, Today!!
Using that rev. assumption and market multiplier, you get a mkt cap value in a range of lets say between $15-21million.

Using the valuation table above, would indicate a fair and reasonable current share price TODAY of around say .07c.

Looking to next yr, let’s say they do $10m or $12m in revs based on prior two yr track record of showing consistent 50% YOY revenue growth…for illustration purposes only, lets use the middle number of $11m in 2025 revs and a 3x multiplier: $11m x 3x = $33m mkt cap…putting this well above .10c

.02 break this week

I’m in.

Movin on up. It looks great

CYIO just posted huge updates coming. This is exciting!!

Looking forward to a solid week